首页 > 文献资料
-
Rho-associated protein kinase is an essential regulator of cytoskeletal dynamics during the process of neurite extension. However, whether Rho kinase regulates microtubule remodeling or the distri-bution of adhesive proteins to mediate neurite outgrowth remains unclear. By specifical y modulat-ing Rho kinase activity with pharmacological agents, we studied the morpho-dynamics of neurite outgrowth. We found that lysophosphatidic acid, an activator of Rho kinase, inhibited neurite out-growth, which could be reversed by Y-27632, an inhibitor of Rho kinase. Meanwhile, reorganization of microtubules was noticed during these processes, as indicated by their significant changes in the soma and growth cone. In addition, exposure to lysophosphatidic acid led to a decreased brane distribution of vinculin, a focal adhesion protein in neurons, whereas Y-27632 recruited culin to the membrane. Taken together, our data suggest that Rho kinase regulates rat hippocampal neurite growth and microtubule formation via a mechanism associated with the redistribution of vinculin.
-
溶血磷脂酸检测异常者对缺血性脑血管病危险因素的认知及其护理干预
溶血磷脂酸(LPA)是修复及组织再生中的重要介质,具有促进血小板凝集、刺激成纤维细胞生长、参与神经系统功能及诱导神经细胞分化等功能[1,2],有致血栓形成和动脉粥样硬化的活性[3].2006年2月7日卫生部发布面向农村和基层推广适宜技术"十年百项计划",其中包含有缺血性脑血管病的预警因子--溶血磷脂酸的临床应用.我院引进了该项目并在临床推广,为缺血性脑血管病的早期预警诊断提供了科学依据[4].2006年10月-2007年10月,对我院缺血性脑血管病预警检测中心的456名LPA异常(++以上)者进行问卷调查,了解其对缺血性脑血管病危险因素LPA认知情况及相关知识的掌握情况,并根据调查情况及时采取护理干预.现报道如下.
-
Expression of lysophosphatidic acid and its receptor in human pancreatic cancer and its clinical evaluation of diagnosis and therapy
Lysophosphatidic acid(LPA) is a naturally occurring phospholipid with diverse effects in various cells, ranging from immediate morphological alteration to long lasting cellular function changes, such as induction of stimulation of cell proliferation, survival, drug resistance and motility. Like many other biomediators, LPA interacts with cells through specific cell surface receptors(G protein-coupled receptors). LPA1/Edg-2,LPA2/Edg-4 and LPA3/Edg-7, named as Edg/LP subfamily, are the three most common lysophosphatidic acid receptors. LPA plays a critical role as a general growth, survival and pro-angiogenic factor in the regulation of pathophysiological processes in vivo and in vitro. Recent literatures suggest that abnormalities in LPA metabolism and function in pancreatic cancer patients may contribute to the initiation and progression of the disease. Thus, LPA might be a potential target for clinical pancreatic cancer diagnosis and therapy. Herein we review the expression of LPA and its receptors in the carcinogenesis of human malignancies, with focus on human pancreatic cancer, and also clinical diagnosis and treatment has been evaluated.